WO2005027970A1 - 癌治療用医薬 - Google Patents
癌治療用医薬 Download PDFInfo
- Publication number
- WO2005027970A1 WO2005027970A1 PCT/JP2004/014452 JP2004014452W WO2005027970A1 WO 2005027970 A1 WO2005027970 A1 WO 2005027970A1 JP 2004014452 W JP2004014452 W JP 2004014452W WO 2005027970 A1 WO2005027970 A1 WO 2005027970A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- igf
- activity
- insulin
- inhibits
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a medicament for treating cancer, which comprises a substance that inhibits the activity of insulin-like growth factor-1 (IGF-I) and insulin-like growth factor-II (IGF-II), and is administered in combination with irradiation. , And insulin-like growth factor-1 (IGF-I) and insulin-like growth factor
- the present invention relates to a drug for treating cancer, which comprises a combination of a substance that inhibits the activity of factor-II (IGF-II) and a substance that has antitumor activity.
- a drug for treating cancer which comprises a combination of a substance that inhibits the activity of factor-II (IGF-II) and a substance that has antitumor activity.
- IGF Insulin-like growth factor
- IGF-I insulin-like growth factor-1
- IGF-II insulin-like growth factor-II
- IGF receptor IGF receptor
- IGFBP IGF-binding protein
- IGF-I and IGF-II are both cancer cells (sarcoma, leukemia, prostate cancer, breast cancer, lung cancer, stomach cancer, esophagus cancer, liver cancer, liver cancer, kidney cancer, kidney cancer, thyroid cancer, brain tumor, ovarian cancer, It has a strong growth-promoting effect on uterine cancer and overexpression has been observed in many cancer cells.
- IGF-family proteins IGF, IGF-R, IGFBP
- IGF-I and IGF-II IGF-family proteins
- IGF-1 and IGF-I IGF-1 and IGF-I.
- Growth factors II and insulin receptors, IGF-IR and IGF-IR receptors, and IGFBPs are intricately intertwined to control disease. That is, it is difficult to completely suppress the disease even if some of these interactions are inhibited.
- sml. 2 As a representative antibody against human IGF-1 (anti-MGF-1 antibody), sml. 2 has been reported (Proceedings of the National Academy of Sciences of the United States of America, 81, 2389). -2392, 1984). sml. 2 has about 40% cross-reactivity with hIGF-II, and lOOng of hIGF-1 can be detected by estanblotting at l ⁇ 2 ⁇ g / mL concentration.
- Va M- SmC121 which does not react with human insulin and hIGF-II, and a peptide containing Leu-Vap Asp at the 10th to 12th positions of hIGF_I.
- 125 1 - WGF- 1 in radioimmuno mediation Si it has been reported that showed sensitivity of HIGF- 1 of Ing / mL (Journal of Endocrinology, 125, 327-335 , 1990).
- HIGF-IR with lg / mL WGF-1 at a concentration of 30 g / mL that completely inhibits the growth of the mouse fibroblast cell line BALB / C3T3 by hIGF-I at a concentration of 12 g / mL or more.
- Inhibition of autophosphorylation of HIGF-I, and radioimmunoassay using 125 I-hIGF-1 have been reported to exhibit a hIGF-I detection sensitivity of 0.1 ⁇ (Hybridoma, 16, 513-518, 1997).
- BPL-M23 exhibits a binding activity of 10.5 litres / dishol for IGF-I, whereas hlGF-II and human insulin have 0.8 and 0.0001% cross-reactivity, respectively. It is responsive to goat, bush, sheep, sheep, magpie, and egret, but not to rat and mouse IGF, and inhibits WGF-I adipogenesis on rat adipocytes (Journal of Molecular Endocrinology, 2, 201-206, 1989).
- S1F2 has been reported as a typical antibody against human IGF-II (anti-hIGF_II antibody). S1F2 has about 10% cross-reactivity with hIGF-I, and can detect 10-100 ng of hlGF-II by Western plotting at a concentration of 1 g / mL. At a concentration of 100 g / mL, it has been shown that 100 ng / mL of hlGF-II inhibits the DNA synthesis-stimulating effect of human fibroblasts (Diabe tes).
- IGF-1 insulin-like growth factor-1
- IGF-II insulin-like growth factor-II
- IGF-1 insulin-like growth factor-1
- IGF-II insulin-like growth factor-1
- An object of the present invention is to provide a cancer treatment drug and a cancer treatment method that synergistically enhance the cancer treatment effect by using a substance that inhibits the activity of child-II (IGF-II).
- the present inventors have conducted intensive studies to solve the above problems, and as a result, irradiated a substance that inhibits the activity of insulin-like growth factor-1 (IGF-I) and insulin-like growth factor-II (IGF-II). Alternatively, they have found that the combined use with a substance having antitumor activity can increase the therapeutic effect on cancer, and have completed the present invention.
- IGF-I insulin-like growth factor-1
- IGF-III insulin-like growth factor-II
- the present invention includes the following inventions (1) to (15).
- a drug for treating cancer which comprises a substance that inhibits the activity of insulin-like growth factor-1 (IGF-I) and insulin-like growth factor-II (IGF-II), and is administered in combination with irradiation.
- IGF-I insulin-like growth factor-1
- IGF-II insulin-like growth factor-II
- a medicament for treating cancer comprising a combination of a substance that inhibits the activity of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-II (IGF-II) and a substance that has antitumor activity.
- IGF-1 insulin-like growth factor-1
- IGF-II insulin-like growth factor-II
- a substance that inhibits the activity of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-II (IGF-II) is selected from the group consisting of the following (a) to (d): (1) The medicament for treating cancer according to any of (4).
- the monoclonal antibody is a monoclonal antibody that binds to an epitope to which a monoclonal antibody produced from Hypridoma KM1468 (FE belly BP-7978) binds.
- the antibody fragment contains Fab, Fab ⁇ F (ab ') 2 , a single-chain antibody (scFv), a dimerization variable region (Di abody), a disulfide stabilized variable region (dsFv), and a CDR.
- the medicament for cancer treatment according to any one of (5) to (7), which is an antibody fragment selected from the group consisting of peptides.
- Low-molecular-weight drugs include DNA alkylating agents, DNA synthesis inhibitors, platinum-based DNA crosslinking agents, antimetabolites, topoisomerase I inhibitors, topoisomerase II inhibitors, tubulin agonists, and hormone antagonists , Aromase inhibitor, immunomodulator, immunosuppressant, steroidal anti-inflammatory, non-steroidal anti-inflammatory, antihistamine, differentiation inducer, proteosome inhibitor, tyrosine kinase inhibitor, adenosine derminer Inhibitors, angiogenesis inhibitors, histone deacetylase inhibitors, matrix protease inhibitors, pharmacosyltransferase inhibitors, bisphosphonate preparations, Hsp90 inhibitors, kinesin Eg5 inhibitors, serine threonine kinase inhibitors
- Insulin-like growth factor-I IGF-I
- insulin-like growth factor-I IGF-I
- a method for treating cancer which comprises administering an effective amount of a substance that inhibits the activity of factor-II (IGF-II) in combination with an effective amount of a substance that has antitumor activity.
- FIG. 1 shows the specific reactivity of the monoclonal antibody to hIGF- ⁇ (binding ELISA).
- the horizontal axis shows the combination of the antibody and the antigen, and the vertical axis shows the binding activity (0D415).
- FIG. 2 shows the reactivity of the monoclonal antibody to hlGF-I having a natural conformation in a liquid phase system (competition ELISA).
- the horizontal axis indicates the concentration of added MGF-1 and the vertical axis indicates the binding activity (0D415).
- FIG. 3 shows the responses of antibodies KM1468 and sml. 2 to WGF-1.
- the horizontal axis shows the antibody concentration (g / mL), and the vertical axis shows the binding activity (0D415).
- ⁇ indicates the reactivity of KM1468, and the mouth indicates the reactivity of sml.2.
- FIG. 4 shows the inhibitory activity of antibodies KM1468 and sml.
- the horizontal axis indicates the concentration of various factors (g / mL), and the vertical axis indicates the binding activity (A indicates hIGF_I, B indicates hlGF-II, C indicates human insulin, and D indicates the activity by mIGF-1.
- ⁇ indicates the reactivity of KM1468, and the mouth indicates the reactivity of sml.2.
- FIG. 5 shows the effect of antibodies KM1468, 31111.2 and 32 on proliferation of human breast cancer cell line MCF7 due to 1116 and human insulin.
- A indicates the cell growth activity of each factor.
- the horizontal axis shows various factor concentrations (ig / mL), and the vertical axis shows proliferation (OD450).
- ⁇ indicates IGF-L
- ⁇ indicates hIGF_II
- the mouth indicates the activity of human insulin.
- B shows the effect of various antibodies on hlGF-1; C, hIGF_II; and D, the proliferation activity of human insulin.
- the horizontal axis shows the antibody concentration (/ ig / mL), and the vertical axis shows the proliferation (OD450).
- the thin dotted line shows the growth without addition of the antibody, and the dotted line shows the growth without addition of each factor.
- ⁇ indicates activity of KM1468, mouth indicates sml. 2, and ⁇ indicates activity of S1F2.
- FIG. 6 shows the effects of antibodies KM1468, sml. 2 and S1F2 on the growth of human colon cancer cell line HT-29 by hlGF and human insulin.
- A is cell proliferation by each factor Show activity.
- the horizontal axis shows various factor concentrations (ng / mL), and the vertical axis shows proliferation (0D450).
- ⁇ indicates hlGF-L Hata indicates hlGF-II activity, and mouth indicates human insulin activity.
- B indicates hlGF-1
- C indicates hIGF_II
- D indicates the effect of various antibodies on the proliferative activity of human insulin.
- the horizontal axis shows the antibody concentration (g / mL), and the vertical axis shows the proliferation (0D450).
- the thin dotted line indicates the growth without the addition of the antibody, and the dotted line indicates the growth without the addition of each factor.
- ⁇ indicates activity of KM1468, mouth indicates sml. 2, and ⁇ indicates activity of S1F2.
- FIG. 7 shows the effects of antibodies KM1468, sml. 2 and S1F2 on the growth of human osteosarcoma cell line MG63 by hlGF and human insulin.
- A shows the cell proliferation activity of each factor.
- the horizontal axis shows various factor concentrations (ng / mL), and the vertical axis shows proliferation (OD450).
- ⁇ has IGF-L ⁇ ha! iIGF-II I, mouth indicates human insulin activity, respectively.
- B shows the effect of WGF-1
- C shows hlGF-II
- D shows the effect of various antibodies on the proliferative activity of human insulin.
- the horizontal axis shows the antibody concentration (g / mL), and the vertical axis shows the proliferation (0D450).
- the thin dotted line shows the growth without addition of the antibody, and the dotted line shows the growth without addition of each factor.
- ⁇ indicates the activity of KM1468
- the mouth indicates the activity of sml. 2
- FIG. 8 shows the inhibitory activity of various peptides on the binding of antibody KM1468 to hIGF- ⁇ .
- the horizontal axis shows the concentration of various peptides (ig / mL), and the vertical axis shows the binding activity.
- the various peptides used are shown in the figure.
- This application claims the priority of Japanese Patent Application No. 2003-332346 filed on September 24, 2003 and includes the contents described in the description and Z or drawings of the patent application.
- the drug for treating cancer of the present invention contains a substance that inhibits the activity of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-II (IGF-II), and is administered in combination with irradiation. For the treatment of cancer.
- IGF-1 insulin-like growth factor-1
- IGF-II insulin-like growth factor-II
- the medicament for treating cancer of the present invention also comprises a substance that inhibits the activity of insulin-like growth factor-1 (IGF-I) and insulin-like growth factor-II (IGF-II), and a substance that has antitumor activity. And a pharmaceutical for treating cancer.
- the "substance inhibiting the activity of IGI and IGF-II” may be a single substance or a composition comprising a plurality of substances. In the case of a composition comprising the above substances, each substance may be used simultaneously or separately.
- Substances that inhibit the activity of IGF-1 and IGF-II include:
- IGF-1 and IGF-II refers to inhibiting any activity of IGF-I and IGF-II, specifically, IGF-1 and IGF-II.
- -II inhibits the cell growth promoting activity.
- the “antibody or antibody fragment that specifically binds to IGF-I and IGF-II and inhibits the activity of IGF-1 and IGF-II” used in the present invention refers to both IGF-1 and IGF- ⁇ .
- An antibody or antibody fragment that specifically binds to and inhibits the activity of both IGF-1 and IGF-II Specifically, antibodies or antibody fragments that recognize the epitopes present in native IGF-I and IGF-II, and antibodies or antibody fragments that recognize the three-dimensional structure of IGF-I and IGF-II, etc. can give.
- the above-mentioned antibody or antibody fragment used in the present invention may be either a polyclonal antibody or a monoclonal antibody, but is preferably a monoclonal antibody.
- monoclonal antibodies include “antibodies produced by Hypridoma” "Body”, “recombinant antibody”, and antibody fragments thereof.
- recombinant gene antibody includes a humanized antibody and a human antibody.
- Humanized antibody includes a human chimeric antibody and a human complementarity determining region (hereinafter, referred to as "humanized antibody”). CDRs) transplant antibodies and the like.
- Hyperidoma refers to the production of a monoclonal antibody with the desired antigen specificity, obtained by cell fusion of B cells obtained by immunizing a non-human mammal with an antigen and myeloma cells Cells.
- Human chimeric antibody refers to the heavy chain variable region (hereinafter referred to as VH) and light chain variable region (hereinafter referred to as VL) of a non-human animal antibody and the heavy chain constant region (hereinafter referred to as VL) of a human antibody.
- the antibody is composed of a light chain constant region (hereinafter referred to as CL) and a light chain constant region (hereinafter referred to as CL).
- CL light chain constant region
- CL light chain constant region
- CL light chain constant region
- CL light chain constant region
- CL light chain constant region
- any CH may be used as long as it belongs to human immunoglobulin (hereinafter, referred to as hlg), but the hlgG class is suitable, and further, gGl and hIgG2 belonging to the MgG class are suitable.
- HI gG3 and M gG4 can be used.
- the CL of the human chimeric antibody may be any CL as long as it belongs to hlg, and a ⁇ class or ⁇ class antibody can be used.
- Animals other than humans include mice, rats, hamsters, and rabbits.
- Human CDR-grafted antibody refers to an antibody obtained by grafting VH and VL CDRs of a non-human animal antibody into appropriate positions of VH and VL of a human antibody.
- the human CDR-grafted antibody of the present invention encodes a V region in which VH and VL CDRs of a non-human animal antibody are linked to a VH and VL framework (hereinafter, referred to as FR) of any human antibody.
- FR VH and VL framework
- any CH may be used as long as it belongs to hlg, but those of the MgG class are preferable, and any of the subclasses such as gGl, hIgG2, hIgG3, and hIgG4 belonging to the WgG class are used. be able to.
- the CL of the human CDR-grafted antibody may be any CL as long as it belongs to Mg, and a ⁇ class or ⁇ class antibody can be used.
- “Human antibody” originally refers to an antibody naturally occurring in the human body, but is a human antibody protein produced by recent advances in genetic engineering, cell engineering, and developmental engineering. Also included are dilibraries and antibodies obtained from human antibody-producing transgenic animals.
- Antibodies present in the human body include, for example, isolation of human peripheral blood lymphocytes, immortalization by infection with EB virus, etc., cloning to obtain lymphocytes that produce the antibodies, and culturing the lymphocytes Then, the antibody can be obtained by purifying the antibody from the culture supernatant.
- the human antibody phage library is a library in which antibody fragments such as Fab and scFv are expressed on the phage surface by inserting an antibody gene prepared from human B cells into the phage gene. From the library, phages expressing antibody fragments having the desired antigen-binding activity on the surface can be recovered using the binding to the substrate on which the antigen is immobilized as an index.
- the antibody fragment can be further converted into a human antibody molecule consisting of two complete H chains and two complete L chains by genetic engineering techniques.
- a human antibody-producing transgenic animal refers to an animal in which a human antibody gene has been integrated into cells.
- a human antibody-producing transgenic mouse can be prepared by introducing a human antibody gene into mouse ES cells, transplanting the ES cells into an early mouse embryo, and then developing the embryo.
- Human antibody-producing transgenic animals can be prepared from human antibody-producing hybridomas by the usual method for preparing hybridomas in non-human animals. Human antibodies can be produced and accumulated.
- Antibodies or antibody fragments that can be preferably used in the present invention bind to monoclonal antibody thigh 1468 produced by Hypridoma KM1468 (FERM BP-7978) and monoclonal antibody KM1468 produced by Hypridoma KM1468 (FERM BP-7978). Reacts with a monoclonal antibody that binds to
- a monoclonal antibody that binds to a binding epitope, a recombinant antibody or an antibody fragment containing the amino acid sequences of CDR1, CD2, and CDR3 of VH and VL of the above-mentioned monoclonal antibody can be used.
- composition includes antibodies or antibody fragments that specifically bind to IGF-I and inhibit IGF-1 activity, and antibodies or antibody fragments that specifically bind to IGF-II and inhibit IGF-II activity
- the composition may be any composition as long as the composition contains any one of an antibody or antibody fragment that inhibits the activity of IGF-I and any one of the antibody or antibody fragment that inhibits the activity of IGF-II. .
- an antibody or antibody fragment that specifically binds to IGF-1 and inhibits the activity of IGF-1 refers to a substance that specifically binds to IGF-1 but does not specifically bind to IGF-II.
- AF791 manufactured by R & D
- mIGF-I mouse IGF-1
- hIGF-1 human IGF-1
- a monoclonal antibody that binds to the epitope that binds AF791 a monoclonal antibody that binds to the epitope that binds 56408, a monoclonal antibody that binds to the epitope that binds M23 / ILG1-001, and the monoclonal antibody described above.
- Examples include a recombinant antibody or an antibody fragment containing the amino acid sequences of CDR1, CDR2, and CDR3 of VH and VL possessed by the oral antibody.
- an antibody or an antibody fragment that specifically binds to IGF-II and inhibits the activity of IGF-II refers to an antibody or antibody fragment that specifically binds to IGF-II but does not specifically bind to IGF-1.
- composition refers to an agent comprising "an antibody or an antibody fragment that specifically binds to IGF-1 and inhibits the activity of IGF-I” and "an agent that specifically binds to IGF-II and An agent containing an "antibody or antibody fragment that inhibits the activity” is separately prepared, and refers to a composition for combining these agents and using them simultaneously or sequentially.
- ⁇ Complexation of an antibody or antibody fragment that specifically binds to IGF-1 and inhibits IGF-1 activity and an antibody or antibody fragment that specifically binds to IGF-II and inhibits IGF-II activity As a ⁇ body, '' a complex obtained by binding any of the antibody or antibody fragment that inhibits the activity of IGF-I and any of the antibody or antibody fragment that inhibits the activity of IGF-II can be used. Anything is acceptable. Specific examples include an antibody complex in which the above two types of antibodies or antibody fragments are bound by the following means.
- Examples of the method of binding the antibody include a method of chemically binding and a method of using a protein engineering technique.
- two kinds of antibody molecules are bonded using a cross-linking agent such as N-succ inimidyl-3-(2-pyridyldithiol) -propionate or S-ace tylmercaptosucc inic acid id anhydride. And the like.
- a cross-linking agent such as N-succ inimidyl-3-(2-pyridyldithiol) -propionate or S-ace tylmercaptosucc inic acid id anhydride.
- any method can be used as long as there is a method in which a plurality of antibodies or antibody fragments are expressed by binding using a protein engineering technique.
- An antibody complex produced by a binding method using a protein engineering technique includes a molecule in which two types of scFvs are bound via a suitable linker, and a type in which two types of antibody Fab 'fragments are bound via a suitable linker.
- an Fc fusion protein in which two types of scFvs are linked to the N-terminus and C-terminus a heteromolecule of an Fc fusion protein in which two types of scFvs are linked, diabody, and diabody are linked to the N-terminus or C-terminus.
- Antibody fragments used in the present invention include Fab, Fab ⁇ F (ab ') 2 , scFv, diabody, dsFv, and peptides including CDRs.
- Fa is a fragment obtained by treating an IgG-type antibody molecule with the protease papain (which is cleaved at the 224th amino acid residue of the H chain). It is an antibody fragment having a molecular weight of about 50,000 and having antigen-binding activity, which is linked by a disulfide bond.
- Fab used in the present invention can be obtained by treating an antibody with proteolytic enzyme papain. Or encoding the Fab of the antibody]) NA is inserted into a prokaryotic or eukaryotic expression vector, and the vector is expressed by introducing the vector into a prokaryotic or eukaryotic organism to produce Fab can do.
- F (ab ') 2 is a fragment obtained by treating an IgG type antibody molecule with the protease pepsin (which is cleaved at the 234th amino acid residue of the H chain), and Fab is a disulfide in the hinge region. It is an antibody fragment having a molecular weight of about 100,000 and having an antigen-binding activity, which is slightly larger than that linked via a bond.
- F (ab ') 2 used in the present invention can be obtained by treating an antibody with the protease pepsin. Alternatively, it can be prepared by linking the following Fab's with a cheese bond or a disulfide bond.
- Fab ' is an antibody fragment having a molecular weight of about 50,000 and having an antigen-binding activity, in which the disulfide bond in the hinge region of F (ab') 2 is cleaved.
- Fab ′ used in the present invention can be obtained by treating F (ab ′) 2 with a reducing agent dithiothreitol.
- DNA encoding the Fab ′ fragment of the antibody is inserted into a prokaryotic expression vector or a eukaryotic expression vector, and the vector is expressed by introducing the vector into a prokaryotic or eukaryotic organism.
- scFv is a VH-P-VL or VL-P-VH polypeptide in which one VH and one VL are linked using an appropriate peptide linker (hereinafter, referred to as P), and binds to antigen.
- P an appropriate peptide linker
- the scFv used in the present invention is obtained by obtaining cDNAs encoding VH and VL of an antibody, constructing a DNA encoding the scFv, inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector,
- the scFv can be produced by introducing the expression vector into a prokaryote or eukaryote and expressing it.
- diabody is an antibody fragment obtained by dimerizing scFv and is an antibody fragment having a bivalent antigen-binding activity.
- the divalent antigen-binding activities can be the same, or one can be a different antigen-binding activity.
- the diabody used in the present invention is obtained by obtaining cDNAs encoding VH and VL of an antibody, constructing a DNA encoding scFv such that the amino acid sequence of the linker has a length of 8 residues or less, and Can be inserted into a prokaryotic expression vector or a eukaryotic expression vector, and the expression vector can be introduced into a prokaryotic ⁇ or eukaryotic organism to express it, thereby producing a diabody.
- dsFv replaces each amino acid residue in VH and VL with a cysteine residue.
- the amino acid residue to be substituted for the cysteine residue can be selected based on the predicted structure of the antibody according to the method shown by Reiter et al. (Prote in Engineering, 7, 697-704, 1994).
- the dsFv used in the present invention is obtained by obtaining cDNAs encoding the VH and VL of the antibody, constructing a DNA encoding the dsFv, and inserting the thigh A into a prokaryotic expression vector or a eukaryotic expression vector.
- dsFv can be produced by introducing the expression vector into a prokaryotic or eukaryotic organism and expressing it.
- the peptide containing CDR comprises at least one region of CDR of VH or VL.
- Peptides containing multiple CDRs can be linked either directly or via an appropriate peptide linker.
- the peptide containing the CDR used in the present invention comprises constructing DNA encoding the VH and VL CDRs of an antibody, inserting the DNA into a prokaryotic expression vector or a eukaryotic expression vector, One can be expressed by introducing it into a prokaryote or a eukaryote to produce a peptide containing CDR.
- the peptide containing CDR can also be produced by a chemical synthesis method such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-butyloxycarbonyl method), and the like.
- Antibodies or antibody fragments used in the present invention include ELISA (Antibodies: A
- the radiation when the above-mentioned substance that inhibits the activity of IGF-1 and IGF-II is used in combination with radiation, the radiation is administered once or before or after administration of a drug containing the substance. Times can be done. Irradiation is performed at a dose of 1 Gy to 10 Gy, preferably 2 to 5 Gy, and more preferably 4 Gy. When performing multiple irradiations, irradiation may be performed by dividing one irradiation amount.
- radiation irradiation refers to a broad concept including irradiation of photons (electromagnetic waves) such as X-rays and ⁇ -rays, and irradiation of particle beams such as electron beams, proton beams, and heavy ion beams.
- photons electromagns
- particle beams such as electron beams, proton beams, and heavy ion beams.
- the substance having an antitumor activity when a substance having an antitumor activity is used in combination with the above substance that inhibits the activity of IGF-1 and IGF-II, the substance having an antitumor activity is a protein or a small molecule drug. Etc. are included.
- anti-tumor activity includes a selective growth-suppressing action or a damaging action on a tissue or a cell of a malignant tumor, and an action of reducing or eliminating a tumor tissue or a cell, and is to be interpreted in the broadest sense.
- Proteins include, but are not limited to, antibodies or cytodynamics.
- TNF lymphotoxin
- interleukin_1 3, 4, 7, 8, 12, 15, 18, 21, granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF) ), Granulocyte-macrophage-colony stimulating factor (GM-CSF), interferon-inducible protein-10 (IP-10), fractal force-in and the like.
- protein preparations such as growth hormone receptor antagonists are included.
- the antibody may be any antibody against an antigen expressed on tumor cells or an antigen involved in tumor pathogenesis such as tumor cell proliferation and metastasis.
- examples include interleukin 6 (IL-6) receptor Body, GD2, GD3, GM2, HER2, CD20, CD22, CD33, CD52, MAGE, HM1.24, parathyroid hormone-related protein (PTHrP), basic fibroblast growth factor, fibroblast growth factor 8, basic Fibroblast growth factor receptor, fibroblast growth factor 8 receptor, epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule (EpCam), insulin-like growth factor, insulin-like growth factor receptor, PMSA And antibodies against vascular endothelial cell growth factor, vascular endothelial cell growth factor receptor and the like.
- IL-6 interleukin 6
- PTHrP parathyroid hormone-related protein
- EGFR epidermal growth factor receptor
- EpCam epithelial cell adhesion molecule
- insulin-like growth factor insulin-like growth
- the scope of the present invention is not limited, and the anti-IL-6 receptor antibody is an anti-cancer research (Anticancer Res.), 18, 1217 (1998), Anti-GD2 antibody is Anticancer Research (Anticancer Res.), 13, 331 (1993), and anti-GD3 antibody is Cancer Immonology (Cancer Immunol. I thigh imother.), 36, 260 (1993), anti-GM2 antibody is Cancer Research (cancer Res.), 54, 1511 (1994), and anti-HER2 antibody is Procedureing Op. National Academy of Sciences (Pro Natl. Acad. Sci. USA), 89, 4285 (1992), anti-CD20 antibody is Blood, 83, 435.
- anti-CD22 antibodies include Seminar's 'in' oncology (Se Thigh in.
- anti-CD33 antibody is published in the journal 'Ob Clinical Oncol. (J. Clin. Oncol.), 19, 3244 (2001), anti-CD52 antibody is published in Proceedings Obb. The National Academy of Sciences (Pro Natl. Acad. Sci. USA), 89, 4285 (1992), anti-MAGE antibody is available from the British 'Janal-Ob' Cancer (British J. Cancer).
- Anti-anti-1.24 antibody is Molecular-Immunologic., 36, 387 (1999), Anti-parathyroid hormone-related protein (PTHrP) antibody is Cancer, 88 , 2909 (2000), Anti-fibroblast growth factor 8 antibody is available from Procedin's' Ob 'The' National 'Academy'Ob' Science (Pro Natl. Acad. Sci. USA), 86, 9911 (1989). The anti-fibroblast growth factor 8 receptor antibody is available from Journal of Biological 'Chemistry (J. Biol. Cem.
- Anti-epithelial cell growth factor receptor antibody is Cancer Res., 59, 1236 (1999), Anti-epithelial cell adhesion molecule antibody is Proceedings-of-the- National Academy of Sciences (Pro Natl. Acad. Sci. USA), 76, 1438 (1979), anti-insulin-like growth factor antibody is available from Journal of Neuroscience and Research (J. Neurosci. Res.), 40, 647 (1995), Anti-insulin-like growth factor receptor antibodies are published in the journal 'OB' Neuroscience 'Research (J. Neurosci. Res.), 40, 647 (1995), anti-PMSA Antibodies are published by Journal of Urology (L Urology), 160, 2396 (1998), Anti-vascular endothelial cell growth factor antibody is Cancer Research
- low-molecular-weight drug examples include, but are not limited to, DNA alkylating agents such as cyclophosphamide, diphosphamide, melphalan, dacarbazine, procarbazine, dimustine, carmustine, oral mucin, estramustine, busulfan, and thiotepa.
- DNA alkylating agents such as cyclophosphamide, diphosphamide, melphalan, dacarbazine, procarbazine, dimustine, carmustine, oral mucin, estramustine, busulfan, and thiotepa.
- Bleomycin, dipromycin, mitomycin (:, DNA synthesis inhibitors such as mitoxantrone; platinum-formulated DNA cross-linking agents such as cisplatin, carpoplatin, oxaliplatin, nedaplatin, etc.); 5-fluorouracil, medicrebin, methotrexetone , Gemushibin, fludarapine, cilatabine, cladribine, mercaptopurine, hydroxycarbamide, Ara-C, etc .; antimetabolite I inhibitors such as irinotecan and nogitecan; doxorubici Topoisomerase II inhibitors such as epirubicin, daunorubicin, etoposide; tubulin agonists such as vincristine, vinblastine, vindesine, vinorelbine, paclitaxel, docetaxel; hormone antagonists such as evening moxifen, goserelin, leuprorelin, flutamide; Aromatas
- Abl inhibitor Flt3 inhibitor, Tyrosine kinase inhibitor such as ZD6474 (VEGFR inhibitor), PD17034 (FGFR inhibitor); Adenosine deminase inhibitor such as pentosuvin; Radicicol, 17- Hsp90 inhibitors such as arylamino-17-demethoxygeldanamycin; angiogenesis inhibitors; histone deacetylase inhibitors; matrix meta-oral protease inhibitors; pharmacosyltransferase inhibitors; bisphosphone preparations; Eg5 inhibitor; UCN-01, rapamycin, etc. Threonine kinase inhibitors and derivatives of these compounds.
- drugs preferably cisplatin, carboblatin, oxaliplatin, 5-fluorouracil, irinotecan, paclitaxel, gefitinib, melphalan, doxorubicin, portezomib, rapamycin, herceptin, mitoxantrone, dexamethasone, UCN-01, precnilone Thalidomide, more preferably, melphalan, cisplatin, mitoxantrone, irinotecan, rapamycin, dexamethasone, UCN-01 and the like.
- a ⁇ medicine for cancer treatment comprising a combination of a substance that inhibits the activity of riGF-I and IGF-II and a substance that has antitumor activity '' refers to ⁇ a substance that inhibits the activity of IGF-1 and IGF-II '' or It refers to a medicament for simultaneously administering the preparation and the “substance having antitumor activity” or the preparation to a subject to be administered, or for sequentially administering with a time lag.
- the administration form of the medicament may be a combination of “a substance that inhibits the activity of IGF-1 and IGF-II” and “a substance that has antitumor activity” at the time of administration.
- a substance that inhibits the activity of IGF-1 and IGF-II a substance that has antitumor activity at the time of administration.
- administration of a single preparation obtained by simultaneously preparing a “substance that inhibits the activity of IGF-I and IGF-II” and a “substance having antitumor activity” ii)
- the time lag depends on the active ingredient to be administered, the dosage form, the administration method, and the like.
- the dosage of the medicament for cancer treatment of the present invention depends on the presence or absence of concurrent irradiation, the type of the substance having anti-tumor activity used, the degree of symptoms, the administration method, the age-sex-weight of the administration target, and the treatment. Depends on the period, etc., and is not particularly limited, but is usually a mammal
- the target disease of the cancer therapeutic drug of the present invention includes various malignant and benign tumors, for example, malignant melanoma, malignant lymphoma, digestive organ cancer, lung cancer, esophagus cancer, stomach cancer, colorectal cancer, rectum cancer, colon cancer, ureter Tumor, gallbladder cancer, bile duct cancer, biliary tract cancer, breast cancer, liver cancer, renal cancer, testicular tumor, maxillary cancer, tongue cancer, lip cancer, oral cancer, pharyngeal cancer, laryngeal cancer, ovarian cancer, uterine cancer, prostate cancer, Thyroid cancer, brain tumor, positiosarcoma, hemangiomas, leukemia, polycythemia vera, neuroblastoma, retinoblastoma, myeloma, cystoma, sarcoma, osteosarcoma, sarcoma, skin cancer, kidney cancer, urinary cancer, Infant cancer, glioma and the like
- the medicament for treating cancer of the present invention is particularly effective for suppressing tumors caused by “WGF-dependent proliferative cancer”.
- HIGF-dependent proliferating cancer refers to a cancer that grows in the presence of hlGF and whose growth rate increases depending on the hlGF concentration, such as prostate cancer, colon cancer, breast cancer, osteosarcoma, and myeloma. can give.
- the medicament for treating cancer of the present invention may be a medicament containing a substance that inhibits the activity of IGF-1 and IGF-II and a substance that has antitumor activity alone as active ingredients, or both. May be used as the active ingredient, but it is usually mixed with one or more pharmacologically acceptable carriers, and any drug well-known in the technical field of pharmaceuticals is used. It is desirable to provide it as a pharmaceutical preparation produced by the method described above.
- a sterile solution dissolved in water or an aqueous carrier such as an aqueous solution of salt, glycine, glucose, human albumin or the like is used.
- pharmacologically acceptable additives such as buffering agents and tonicity agents to bring the formulation solution closer to physiological conditions, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, quencher Sodium acid or the like can also be added. It can also be stored after lyophilization and dissolved in an appropriate solvent before use.
- formulation suitable for oral administration include emulsions, syrups, capsules, tablets, powders, and granules.
- liquid preparations such as emulsions and syrups include water, sugars such as sucrose, sorbitol, and fructose; dalicols such as polyethylene glycol and propylene glycol; oils such as sesame oil, olive oil and soybean oil; It can be manufactured using preservatives such as p-hydroxybenzoic acid esters and flavors such as strawberry flavor and peppermint as additives.
- sugars such as sucrose, sorbitol, and fructose
- dalicols such as polyethylene glycol and propylene glycol
- oils such as sesame oil, olive oil and soybean oil
- preservatives such as p-hydroxybenzoic acid esters and flavors such as strawberry flavor and peppermint as additives.
- excipients such as lactose, glucose, sucrose, mannitol, disintegrants such as starch, sodium alginate, lubricants such as magnesium stearate, talc, polypi It can be produced using a binder such as nyl alcohol, hydroxypropylcellulose, or gelatin, a surfactant such as a fatty acid ester, or a plasticizer such as glycerin as an additive.
- Formulations suitable for parenteral administration include injections, suppositories, sprays and the like.
- an injection is prepared using a carrier comprising a salt solution, a glucose solution, or a mixture of both.
- Suppositories are prepared using carriers such as cocoa butter, hydrogenated fats or carboxylic acids.
- Sprays are prepared using the inhibitor itself or a carrier that does not irritate the oral and respiratory mucosa of the recipient and disperses the inhibitor as fine particles to facilitate absorption.
- Specific examples of the carrier include lactose and glycerin.
- preparations such as aerosols and dry powders are possible.
- the components exemplified as additives for oral preparations can be added.
- a mammal is administered in combination with an effective amount of a substance that inhibits the activity of IGF-1 and IGF-II and an effective amount of a substance having antitumor activity.
- a method of treating cancer and administering, simultaneously or sequentially, an effective amount of a substance that inhibits the activity of IGF-1 and IGF-II and an effective amount of a substance that has antitumor activity.
- a method of treating cancer is also provided.
- the term "mammal” refers to mammals such as humans, dogs, cats, cats, sheep, goats, goats, pests, horses, and the like having cancer
- the "effective amount” refers to It refers to an amount that, by administration of the above substance to cancer cells, stops the growth of cancer cells and reduces or eliminates the size of a tumor.
- IGF-1 and IGF which are ones of the substances used in the present invention that specifically bind to IGF-I and IGF-II and inhibit the activity of IGF-I and IGF-II, -A method for preparing an antibody or antibody fragment that specifically binds to II and inhibits the activity of IGF-1 and IGF-II, and the activity evaluation.
- An expression vector containing a cDNA encoding IGF can be introduced and expressed in E. coli, yeast, insect cells, animal cells, and the like to obtain a recombinant IGF protein, which can be used as an antigen.
- a synthetic peptide having an IGF partial sequence can be used as an antigen.
- the antigenic moiety peptide in order to obtain an antibody which recognizes the protein in a state of a native structure protein partial sequence of approximately 5 to 30 residues is not D denatured is selected, It is necessary to select a partial sequence existing on the surface of the protein in a three-dimensional structure as an antigen peptide.
- the portion present on the protein surface in the three-dimensional structure can be estimated by predicting a highly hydrophilic partial sequence using commercially available protein sequence analysis software such as Genetyx Mac.
- the part with low hydrophilicity is often present inside the protein due to its three-dimensional structure, and the part with high hydrophilicity is often present on the surface of the protein.
- the selected partial peptide is not always the antigen that establishes the desired antibody.
- a cysteine is added to the end of the partial peptide to crosslink with the protein.
- the N-terminal of the peptide is acetylated and the C-terminal is amidated as necessary.
- the partial peptide can be synthesized by a general liquid phase, solid phase peptide synthesis method, a method of appropriately combining them, or a method analogous thereto (The Peptides, Analys is, Synthes is, Biolgy, Vol. 1, 1979; Vol. 2, 1980; Vol. 3, 1981, Academic Press; Basics and Experiments on Peptide Synthesis, Maruzen, 1985; Development of Continuing Pharmaceuticals, Vol.
- a commercially available peptide synthesizer such as a peptide synthesizer manufactured by Biosystems, In (hereinafter referred to as ABI) or a peptide synthesizer manufactured by Advanced ChemTech Inc. (hereinafter referred to as ACT) It can be carried out according to the respective synthesis programs using a chain-protected N «-Fmoc-amino acid or ⁇ -Boc-amino acid.
- Protected amino acids and carrier resins as raw materials can be obtained from ABI, Shimadzu, Kokusan Chemical, Nova Biochem, Watanabe Chemical, ACT, Peptide Research Institute, and the like.
- the protected amino acids, protected organic acids, and protected organic amines used as raw materials can be synthesized according to or according to the reported synthetic methods (The Peptides, Analysis, Synthesis, Biology, Vol. 1, 1979). Vol. 2, 1980; Vol. 3, 1981, Academic Press; Fundamentals and Experiments of Peptide Synthesis, Maruzen, 1985; Development of Continuing Drugs, Vol. 14, Peptide Synthesis, Hirokawa Shoten, 1991; International Journal of Peptide ⁇ Protein Research, 35, 161-214, 1990).
- the animal used for immunization may be any animal, such as a mouse, a rat, a hamster, or a rabbit, as long as it can produce a hybridoma.
- a mouse or rat aged 3 to 20 weeks is immunized with the antigen prepared in 1 (1) above, and antibody-producing cells are collected from the spleen, lymph nodes, and peripheral blood of the animal. Immunization is performed by subcutaneously, intravenously or intraperitoneally administering the antigen several times to the animal with an appropriate adjuvant.
- an adjuvant As an adjuvant, Freund's complete adjuvant
- BSA Plasma Freund "s Adjuvant
- KLH Keyhole Limpet Hemocyanin
- Conjugates can be prepared as an immunogen by preparing a conjugate with a carrier protein, such as, etc. Blood is collected from the fundus venous plexus or tail vein of the immunized animal 3 to 7 days after administration of each antigen and used as an antigen. The reactivity to the used hlGF is confirmed by ELISA or the like, and the mouse or rat whose serum shows a sufficient antibody titer is used as the source of the antibody-producing cells.
- myeloma cells a cell line obtained from a mouse, 8-azaguanine-resistant myeloma cell line P3-X63Ag8-Ul (P3-U1) (European Journal of Immunology, 6, 511-519, 1976), SP2 / 0-Agl4 (SP-2) (Nature, 276, 269-270, 1978), P3-X63-Ag8653 (653) (Journal of Immunology, 123, 1548-1550, 1979), P3-X63-Ag8 ( X63) (Nature, 256, 495-497, 1975) and any other myeloma cells that can grow in vitro. Culture and passage of these cell lines are performed according to a known method (Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory, 1988), and a cell number of 2 ⁇ 10 7 or more is secured by the time of cell fusion.
- a cell-aggregating medium such as polyethylene glycol-1000 (hereinafter abbreviated as PEG-1000) is added, and the cells are fused to form a cell culture medium.
- PEG-1000 polyethylene glycol-1000
- MEM Modified Eagle's Medium
- PBS Phosphate Buffered Saline
- a HAT medium normal medium [1.5 mM glutamine, 50 M 2_mercaptoethanol, 10 M medium containing g / mL gentamicin and 10% fetal bovine serum (hereinafter referred to as FBS)] containing 0.4 lmM hypoxanthine, 15 M thymidine and 0.4 ⁇ aminopterin).
- FBS fetal bovine serum
- the culture After the culture, a part of the culture supernatant is removed, and a sample that reacts with the antigen protein by ELISA and does not react with the non-antigen protein is selected. Next, the cells were converted into single cells by the limiting dilution method, and those with a stable high antibody titer confirmed by ELISA were monoclonal antibodies. Select as a production hybridoma.
- the antigen is immobilized on a 96-well ELISA plate and reacted with the culture supernatant of a hybridoma or purified antibody as the primary antibody. After the first antibody reaction, wash the plate and add the second antibody.
- an antibody that can recognize the first antibody and that is labeled with biotin, an enzyme, a chemiluminescent substance, a radioisotope, or the like is used. Specifically, if a mouse is used for preparing the hybridoma, an antibody that can recognize the mouse antibody is used as the second antibody. After the reaction, a reaction is performed according to the labeling substance of the second antibody, and the antibody is selected as a hybridoma that produces a monoclonal antibody that specifically reacts with the antigen.
- hybridoma KM1468 Specific examples include hybridoma KM1468.
- Hypri-Dorma KM1468 was registered on March 26, 1994 by the National Institute of Advanced Industrial Science and Technology, Patent Organism Depositary (Tsukuba-Higashi 1-1-chome, Ibaraki Pref. It has been deposited as FERM BP-7978 on 5 6 6).
- pristane (2,6,10,14-tetramethylpentyldecane) was intraperitoneally administered to 8- or 10-week-old mice or nude mice reared for 2 weeks.
- the anti-hIGF monochromator port one monoclonal antibody-producing High Priestess dormer cells 5 X 10 S ⁇ 2 X 10 7 cells / animal that was injected intraperitoneally.
- the hybridoma becomes ascites cancer.
- the subclass of the purified monoclonal antibody can be determined using a mouse monoclonal antibody typing kit or a rat monoclonal antibody typing kit.
- the protein concentration can be calculated by the Lowry method or from the absorbance at 280 ⁇ .
- the antibody subclass refers to an isotype within the class, and includes IgGl, IgG2a, IgG2b, and IgG3 for mice and IgGK IgG2, IgG3, and IgG4 for humans.
- the binding activity of the anti-hlGF monoclonal antibody in the culture supernatant or purified to hlGF was determined by ELISA and surface plasmon resonance (Journal of
- the reactivity with hlGF and the antigen epitope can be analyzed by competitive ELISA using hlGF and a partial peptide of hlGF.
- Whether or not the antibody recognizes the three-dimensional structure of hlGF can be estimated by commonly used three-dimensional structural analysis methods or by combining various immunological methods. Examples of the three-dimensional structure analysis method include X-ray crystallography and nuclear magnetic resonance. Examples of a method for combining various immunological measurement methods include a method for combining an ELISA method for a non-denatured antigen and an ELISA method for a denatured antigen.
- an antibody that shows reactivity only to the non-denatured antigen has a high possibility of recognizing the three-dimensional structure of the antigen.
- the ELISA method for a non-denatured antigen include an ELISA method in which a non-denatured antigen is reacted with an antibody in a liquid layer.
- any ELISA method can be used as long as the antibody reacts in a state where the antigen does not retain the original three-dimensional structure.
- directly immobilized on a hydrophobic reaction plate ELISA methods for antigens that have been converted, or partial peptides that have been digested to an appropriate length are examples of the ELISA method for a non-denatured antigen.
- the antibody used in the present invention can be obtained by selecting an antibody having a binding activity to hIGF- ⁇ and a binding activity to MGF-1 by the binding activity measurement method or competition ELISA. Further, by examining the effect on a cell line showing hIGF-dependent proliferation, the activity of inhibiting the activity of MGF in vitro can be measured.
- Cell lines showing hIGF-1 or hIGF-II-dependent proliferation include human breast cancer cell line MCF7 (ATCC HTB-22), human colon cancer cell line HT-29 (ATCC HTB-38) and the like.
- an activity of inhibiting hIGF activity in vivo can be measured by establishing an hIGF-dependent cell proliferation measurement system using an animal such as a mouse and examining the effect on the measurement system.
- Polyclonal antibodies can be prepared from sera of animals whose sera showed a sufficient antibody titer among animals immunized by the method described in 1. (2) above.
- a serum fractionated by centrifugation from blood collected from the animal, or an immunoglobulin fraction from the serum according to a conventional method can be purified to prepare a polyclonal antibody.
- the activity of the polyclonal antibody can be evaluated for its antigen-binding activity by the method described in 1. (7) above.
- the humanized antibody expression vector may be any expression vector for animal cells into which a gene encoding human antibody CH, Z or CL is incorporated.
- the humanized antibody expression vector can be constructed by cloning the genes encoding the human antibody CH and CL into animal cell expression vectors, respectively.
- the C region of the human antibody can be CH and CL of any human antibody.
- the C region of the IgGl subclass of the H chain of the human antibody hereinafter, referred to as liCrl
- hCK the L chain of the human antibody / c class C region
- genes encoding CH and CL of the human antibody chromosomal DNA consisting of exon and intron can be used, and cDNA can also be used.
- Any expression vector for animal cells can be used as long as it can integrate and express a gene encoding the C region of a human antibody.
- PAGE 107 (Cytotechnol ogy, 3, 133-140, 1990)
- pAGE103 (Journal of Biochemistry, 101, 1307-1310, 1987)
- pHSG274 (Gene, 27, 223-232, 1984)
- pKCR Proceedings of the National Academy of Sciences of the United States of America, 78, 1527-1531, 1981
- pSGl / 3 d2-4 Cyto technology, 4, 173-180, 1990.
- Promoters and enhancers used in animal cell expression vectors include the SV40 early promoter and enhancer.
- tandem type As the humanized antibody expression vector, either the type in which the antibody H chain and the L chain are present on separate vectors or the type in which the antibody H and L chains are present on the same vector (hereinafter, referred to as tandem type) can be used. However, tandem humanization is achieved due to the ease of construction of a humanized antibody expression vector, ease of introduction into animal cells, and the balance of antibody H chain and L chain expression levels in animal cells. Antibody expression vectors are preferred (Journal of Immunological Methods, 167, 271-278, 1994). As a vector for expressing an evening humanized antibody, PKANTEX93 (W097 / 10354),
- the constructed humanized antibody expression vector can be used for expression of a human chimeric antibody and a human CDR-transplanted antibody in animal cells.
- CDNAs encoding non-human animal antibodies for example, VH and VL of mouse antibodies, are obtained as follows.
- Extract mRNA from hybridomas producing mouse antibodies and synthesize cDNA Cloning the synthesized cDNA into a vector such as a phage or a plasmid creates a cDNA library. A recombinant phage or a recombinant plasmid containing cDNA encoding VH and a cDNA encoding VL using the C region or V region of the mouse antibody as a probe The isolated recombinant phage or recombinant plasmid is isolated.
- the entire nucleotide sequence of VH and VL of the target mouse antibody on the recombinant phage or recombinant plasmid is determined, and the entire amino acid sequence of VH and VL is deduced from the nucleotide sequence.
- Methods for preparing total A from hybridomas include guanidine thiocyanate-cesium trifluoroacetate method (Methods in Enzymology, 154, 3-28, 1987), and methods for preparing mRNA from total RNA include oligo (dT ) Immobilized cellulose force column method (Molecular Cloning: ALaboratory Manual, Cold Spring Harbor Lab. Press New York, 1989).
- Kits for preparing mRNA from hybridomas include Fast Track mRNA Isolation Kit (Invitrogen), Quick Prep mRNA Purification Kit (Pharmacia) and the like.
- any vector can be used as a vector for incorporating a cDNA synthesized as a type III mRNA extracted from a hybridoma, as long as the vector can incorporate the cDNA.
- ZAP Express (Strategies, 5, 58-61, 1992), pBluescript II SK (+) (Nucleic Acids Research, 17, 9494, 1989), AZAP II (Stratagene), AgtlO, Agtll (DNA Cloning: A
- Escherichia coli to which a cDNA library constructed by a phage or a plasmid vector is introduced can be introduced, expressed and maintained. Any one can be used as long as For example, XU-Blue MRF '
- Methods for selecting cDNA clones encoding VH and VL of non-human animal antibodies from the cDNA library include colony hybridization using radioisotope or fluorescently labeled probes or plaque hybridization. Pressing New York, 1989) can be selected according to the solution method (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Lab. Press New York, 1989).
- a primer or a cDNA library or a cDNA library synthesized from mRNA is prepared as a type III and subjected to Polymerase Chain Reaction (hereinafter referred to as PCR method;
- VH and VL can also be prepared.
- the cDNA selected by the above method is cleaved with an appropriate restriction enzyme or the like, cloned into a plasmid vector such as pBluescript SK (-) (manufactured by Stratagene), and subjected to a commonly used nucleotide sequence analysis method, for example, the dideoxy method ( Proceedings of the
- the BLAST method (Journal of Japan) can be performed on any database, for example, SWISS-PR0T or PIR-Protein.
- a cDNA encoding VH and VL of a non-human animal antibody is cloned upstream of the gene encoding CH and CL of the human antibody in the humanized antibody expression vector described in 2 (1) above, and a human chimera is obtained.
- An antibody expression vector can be constructed.
- the cDNA encoding the VH and VL of the antibody of a non-human animal can be obtained by combining the nucleotide sequence at the 3 'end of the VH and VL of the antibody of a non-human animal with the nucleotide at the 5' end of CH and CL of the human antibody.
- VH and VL of the human CDR-grafted antibody can be constructed as follows. First, the VH and VL antibodies of the target non-human animal Select the FR amino acid sequence of VH and VL of the human antibody to which the CDR amino acid sequence is to be transplanted. As the amino acid sequence of FR of human antibody VH and VL, any amino acid sequence can be used as long as it is derived from human antibody.
- amino acid sequences of the FRs of VH and VL of human antibodies registered in databases such as Protein in Data Bank, and the common amino acid sequence of each subgroup of FR of VH and VL of human antibodies (I ( Sequences of Proteins of Immunological Interfaces, US Dep.Health and Human Services, 1991) .
- amino acid sequences of the FRs of VH and VL of human antibodies registered in databases such as Protein in Data Bank, and the common amino acid sequence of each subgroup of FR of VH and VL of human antibodies (I ( Sequences of Proteins of Immunological Interfaces, US Dep.Health and Human Services, 1991) .
- VH and VL CDR amino acid sequences of the target non-human animal antibody are grafted to the FR amino acid sequence, and the VH and VL amino acid sequences of the human CDR-grafted antibody are designed.
- Design a base sequence encoding the amino acid sequence of VH and VL Based on the designed base sequence, synthesize several synthetic DNAs each having a length of about 100 bases and use them for PCR. In this case, it is preferable to design six synthetic DNAs for both VH and VL in view of the reaction efficiency in PCR and the length of DNA that can be synthesized.
- a human CDR-grafted antibody is obtained by transplanting only the VH and VL CDRs of the target non-human animal antibody to the human antibody VH and VL FRs, and the antigen-binding activity of the non-human animal is not Is known to be reduced compared to other antibodies (BIO / TECHNOLOGY, 9, 266-271, 1991). This is due to the fact that not only the CDRs but also some amino acid residues of FR are directly or indirectly involved in antigen-binding activity in VH and VL of the original non-human animal antibody. It is considered that amino acid residues are changed to different amino acid residues in FR of human antibody VH and VL with CDR transplantation.
- human CDR-grafted antibodies have the amino acid residues involved in direct binding to antigens and the amino acid residues of CDR in the amino acid sequence of FRs of VH and VL of human antibodies. Identify amino acid residues that act or maintain the antibody conformation and indirectly participate in antigen binding, and modify them to those found in the original non-human animal antibody. It has been reported to increase the decreased antigen binding activity (BI0 / TECHN0L0GY, 9, 266-271, 1991). In the production of human-type CDR-grafted antibodies, the most important point is how to efficiently identify the amino acid residues of FR involved in the antigen-binding activity.
- the modification of FR amino acid residues of VH and VL of a human antibody can be achieved by performing the PCR method described in 2 (4) above using synthetic DNA for modification. Determine the nucleotide sequence of the amplified product after PCR by the method described in 2 (2) above, and confirm that the desired modification has been performed.
- cDNAs encoding VL and VL can be cloned to construct a human CDR-grafted antibody expression vector.
- the humanized antibody expression vector described above can be cloned upstream of the genes encoding CH and CL of the human antibody so that they can be expressed in an appropriate form.
- the humanized antibody expression vectors described in 2 (3) and (6) above or expression vectors modified from them were used. Transient expression of a humanized antibody can be performed. As the host cell into which the expression vector is introduced, any cell can be used as long as it can express the humanized antibody.However, COS-7 cells (ATCC CRL1651) can be used due to the high expression level. Commonly used (Methods in Nucleic Acids Research, CRC press, 283, 1991).
- Methods for introducing the expression vector into COS-7 cells include the DEAE-dextran method (Methods in Nucleic Acids Research, CRC press, 283, 1991) and the Lipofexion method (Proceedings of the National Academy of Sciences of the United States of America). , 84, 7413-7417, 1987). After the introduction of the expression vector, the expression level and antigen-binding activity of the humanized antibody in the culture supernatant were determined by ELISA (Antibodies: ALaboratory Manual, Cold Spring Harbor
- transformed cells that stably express the humanized antibody can be obtained.
- a method for introducing an expression vector into a host cell there is an electoporation method (Cytotechnology, 3, 133-140, 1990).
- the host cell into which the humanized antibody expression vector is introduced any cell can be used as long as it can express the humanized antibody.
- mouse SP2 / 0-Agl4 cells ATCC CRL1581
- mouse P3X63-Ag8.653 cells ATCC CRL1580
- CH0 cells deficient in dihydrofolate reductase gene hereinafter referred to as dMr
- dMr dihydrofolate reductase gene
- the transformant that stably expresses the humanized antibody contains a drug such as G418 sulfate (hereinafter, referred to as G418) according to the method disclosed in JP-A-2-257891. It can be selected by culturing in an animal cell culture medium.
- RPMI1640 medium manufactured by Nissui Pharmaceutical
- GIT medium manufactured by Nippon Yakuhin
- EX-CELL302 medium manufactured by JRH
- IMDM manufactured by GIBCO BRL
- Hybridoma-SFM Manufactured by GIBCO BRL
- a medium obtained by adding various additives such as FBS By culturing the obtained transformed cells in a medium, humanized antibodies can be expressed and accumulated in the culture supernatant. The expression level and antigen-binding activity of the humanized antibody in the culture supernatant can be measured by ELISA.
- the transformed cells can increase the expression level of the humanized antibody using a dMr amplification system or the like according to the method disclosed in Japanese Patent Application Laid-Open No. 2-2577891.
- Humanized antibodies can be purified from the culture supernatant of transformed cells using a protein A column (Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 8, 1988; Monoclonal Antibodies: Principles and Practice, Academic Press Limited, 1996).
- protein A column Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 8, 1988; Monoclonal Antibodies: Principles and Practice, Academic Press Limited, 1996.
- other purification methods usually used for protein purification can be used.
- purification can be performed by a combination of gel filtration, ion exchange chromatography, and ultrafiltration.
- the molecular weight of the purified humanized antibody H-chain, L-chain or the entire antibody molecule can be determined by polyacrylamide gel electrophoresis (hereinafter referred to as PAGE: Nature, 227, 680-685, 1970) or Western blotting (Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Chapter 12, 1988; Monoclonal Antibodies: Principles and Practice, Academic Press Limited, 1996).
- the activity of the humanized antibody can be evaluated in the same manner as in 1 (7) above. 4. Preparation of antibody fragments
- Antibody fragments can be prepared by genetic engineering techniques or protein chemical techniques based on the anti-hlGF antibodies described in 1 and 2 above.
- Examples of genetic engineering techniques include constructing a gene encoding the desired antibody fragment, and expressing and purifying it using an appropriate host such as animal cells, plant cells, insect cells, and Escherichia coli. .
- proteochemical techniques include site-specific cleavage and purification using proteolytic enzymes such as pepsin and papain.
- a method for producing a peptide containing Fab, F (ab ') 2 , Fab', scFv, diabody, dsFv, and CDR as antibody fragments will be specifically described below.
- Fabs can be produced proteinically by treating IgG with proteolytic enzyme papain. After papain treatment, if the original antibody is an IgG subclass having protein A binding, it can be separated from IgG molecules and Fc fragments by passing through a protein A column and recovered as a homogeneous Fab ( Monoclonal Antibodies: Principles and Practice, third edition, 1995). In the case of IgG subclass antibodies without protein A binding, Fab can be recovered in fractions eluted at low salt concentration by ion exchange chromatography.
- Fabs can be produced by genetic engineering, mostly using Escherichia coli, or using insect cells or animal cells. For example, 2 (2), 2 (4) and 2 above
- the DNA encoding the V region of the antibody described in (5) can be cloned into a Fab expression vector to prepare a Fab expression vector.
- a Fab expression vector any vector can be used as long as it is capable of incorporating and expressing NA)] NA for Fab.
- An example is IT106 (Science, 240, 1041-1043, 1988).
- the Fab expression vector can be introduced into an appropriate Escherichia coli to produce and accumulate Fab in an inclusion body or periplasm. Active Fabs can be converted from inclusion bodies into active Fabs by the refolding method usually used for proteins, and when expressed in periplasm, active Fabs leak into the culture supernatant. . Rifo After one rounding or from the culture supernatant, a homogeneous Fab can be purified by using an antigen-bound column (Antibody Engineering, A.
- F (ab ') 2 can be produced proteinically by treating IgG with the protease pepsin. '' After treatment with pepsin, it can be recovered as homogeneous F (ab ') 2 by the same purification procedure as Fab (Monoclonal Antibodies: Principles and Practice, third edition, Academic Press, 1995) ⁇
- it can also be produced by a method of performing SS bonding (Antibody Engineering, A Practical Approach, IRL PRESS, 1996).
- Fab ′ can be obtained by treating F (ab ′) 2 described in 3 (2) above with a reducing agent such as dithiothreitol.
- Fab ′ can be produced by genetic engineering, mostly using Escherichia coli, or insect cells or animal cells. For example, clone the DNA encoding the V region of the antibody described in 2 (2), 2 (4) and 2 (5) above into a Fal) 'expression vector to prepare a Fab' expression vector. Can be.
- the Fab 'expression vector any vector can be used as long as it can incorporate and express Fab' DNA.
- An example is PAK19 (BIO / TECHNOLOGY, 10, 163-167, 1992).
- the Fab 'expression vector can be introduced into an appropriate E.
- the inclusion bodies can be converted into active Fab's by the refolding method usually used for proteins, and when expressed in periplasm, lysozyme partial digestion, osmotic shock, sonication, etc.
- the bacteria can be crushed by the treatment and collected outside the cells. Uniform Fab 'can be purified after refolding or from bacterial lysate by using a protein G column, etc.
- Preparation of scFv ScFv can be produced by genetic engineering using phage or Escherichia coli, or insect cells or animal cells. For example, 2 (2), 2 (4) and 2 above
- the thigh A encoding the V region of the antibody described in (5) can be cloned into a scFv expression vector to prepare a scFv expression vector.
- Any scFv expression vector can be used as long as it can incorporate and express scFv DNA.
- PCANTAB5E Pulacia
- pHFA Human Fatty Acid
- scFv expression vector By introducing the scFv expression vector into a suitable E. coli and infecting it with a helper phage, it is possible to obtain a phage that expresses the scFv on the phage surface in a form fused with the phage surface protein.
- scFv can be produced and accumulated in the inclusion body or periplasm of Escherichia coli into which the scFv expression vector has been introduced.
- the inclusion body can be converted into an active scFv by the refolding method usually used for proteins, and when expressed in periplasm, partial digestion with lysozyme, osmotic shock, sonication Bacteria can be crushed by such treatments and collected outside the cells. Uniform scFv can be purified from lysate after refolding or by using cation exchange chromatography, etc.
- diabody can be prepared using Escherichia coli, insect cells or animal cells.
- a DNA is prepared by linking VH and VL of the antibodies described in 2 (2), 2 (4) and 2 (5) above so that the number of amino acid residues encoded by the linker is 8 or less.
- a diabody expression vector can be prepared.
- any vector can be used as long as it can incorporate and express diabody DNA.
- CANTAB5E Pulacia
- pHFA Human Antibodies Hybridomas, 5, 48, 1994
- the diabody can be produced and accumulated in the inclusion body or periplasm of E.
- an active diabody can be obtained by the refolding method usually used for proteins, and when expressed in periplasm, Bacteria can be disrupted by partial digestion with zozyme, osmotic shock, sonication, etc., and collected outside the cells. After refolding or from the lysate of bacteria, a uniform scFv can be purified by cation exchange chromatography (Antibody Engineering, A Practical
- dsFv can be prepared using Escherichia coli, insect cells or animal cells. First, a mutation is introduced at an appropriate position in the DNA encoding VH and VL of the antibody described in 2 (2), 2 (4) and 2 (5) above, and the encoded amino acid residue is substituted with cysteine. Make DNA. Each of the prepared DNAs can be cloned into a dsFv expression vector to prepare VH and VL expression vectors.
- the dsFv expression vector any vector can be used as long as it can incorporate and express dsFv DNA. For example, pULI9 (Prote in Engineering, 7, 697-704, 1994) can be mentioned. VH and VL expression vectors can be introduced into appropriate E.
- VH and VL can be obtained from inclusion bodies or periplasm, mixed, and converted into active dsFv by the refolding method usually used for proteins. After refolding, it can be further purified by ion exchange chromatography and gel filtration (Prote in Engineering, 7, 697-704, 1994).
- the peptide containing the CDR can be prepared by a chemical synthesis method such as the Fmoc method or the tBoc method. Also, a DNA encoding a peptide containing CDR can be prepared, and the prepared DNA can be cloned into an appropriate expression vector to prepare a CDR peptide expression vector. Any expression vector can be used as long as it can incorporate and express ⁇ A encoding the CDR peptide. Examples include LEX (Invitrogen) and AX4a + (Invitrogen). The expression vector can be introduced into an appropriate Escherichia coli to produce and accumulate in an inclusion body or periplasm. CDR peptide is obtained from inclusion body or periplasm. Purified by on-exchange chromatography and gel filtration
- Example 1 Examination of the combined effect of radiation and anti-IGF-1 monoclonal antibody
- the epidermoid carcinoma cell line A431 cells (ATCC CRL-1555) were cultured in a 10 cm dish and became 703 ⁇ 4 confluent.
- Example 2 Examination of the combined effect of a low-molecular-weight drug and an anti-IGF-1 monoclonal antibody A 96-well culture plate was mixed with a serially diluted drug and a serially diluted anti-IGF monoclonal antibody KM1468. L / Pell was added at a time. Furthermore, multiple myeloma cell line LP-1 cells (DSMZ ACC41) were added at 100 / xL / well (10000 cells) and cultured at 37 ° C for 3 days. After culturing, add Cell Proliferation Reagent WST-1 (Roche) at 20 / iL / well and incubate at 37 ° C for 2-3 hours.
- DSMZ ACC41 multiple myeloma cell line LP-1 cells
- Concomitant medications include melphalan, 'Dimustine, doxorubicin,' mitoxantrone, vinorelbine, etoposide, paclitaxel, dexamethasone, 5-fluorouracil, methotrexate, gemcitabine, cisbratin, thalidomide, 7-ethyl- 10- Hydroxycamptothecin (active form of irinotecan; hereinafter abbreviated as SN-38; Cancer Researc, 50, 1715-1721, 1990), rapamycin, radicicol, 17-arylamino-17-demethoxygeldanamycin (hereinafter, referred to as Abbreviated as 17AAG; Cancer Cliemot erapy & Pharmacology, 42, 273-279, 1998), UCN-01 (Journal of Antibiotics, 40, 1782-1784, 1987), PD173074 (EMB0 Journal, 17, 5896-5904, 1998) ), Z
- Example 3 Examination of administration method in combination use of low-molecular-weight drug and anti-IGF-1 monoclonal antibody Multiple myeloma cell line LP-1 cells (DSMZ ACC41) were placed in a 96-well culture plate using IOO L / well. (10000 cells) were seeded, doxorubicin and anti-IGF monoclonal antibody KM1468 were added, and the cells were cultured at 37 ° C for 3 days. Doxorubicin and KM1468 were added to the medium by the following three methods.
- Method 1 Cells were cultured on day 1 in 150 xL medium supplemented with doxorubicin alone, and on days 2 and 3 cells were cultured in 200 zL medium supplemented with doxorubicin and KM1468
- Method 2 Day 1 The cells were cultured in 150 iL of medium supplemented with KM1468 alone, and on the second and third days in 200 / zL of medium supplemented with doxorubicin and KM1468.
- Method 3 Cells were cultured for 3 days in a medium containing doxorubicin and KM1468 (the medium volume on the first day was 150 iL, and the second and third days were 200 / L each).
- doxorubicin and KM1468 were added so that the final concentrations were 1 mol / L and 1 g / mL.
- the cells were added with a cell proliferation reagent WST-1 (manufactured by Roche) at 20 ⁇ 17 ⁇ l each and cultured for 2 to 3 hours, and the OD450 was measured using a microplate reader M-SPmax250 (manufactured by Molecular Devices).
- WST-1 cell proliferation reagent
- M-SPmax250 manufactured by Molecular Devices
- Method 3 In any of the administration methods, cell proliferation was more strongly inhibited when used together than when used alone. From the above, it was confirmed that both the administration methods of the low-molecular-weight drug and the anti-IGF monoclonal antibody are useful for cancer treatment.
- methylated BSA-hIGF-I (equivalent to 100 / ig of hIGF-1) prepared as above using complete Freund's adjuvant was administered, and 2 weeks later.
- Blood was collected from the fundus venous plexus, and the antibody titer in the serum was examined by the binding ELISA shown in Reference Example 1 (4).
- the spleen was extracted 3 days after the last immunization from the rat showing a sufficient antibody titer.
- the spleen is shredded in MEM medium (manufactured by Nissui Pharmaceutical Co., Ltd.), loosened with forceps, centrifuged (1200 rpm, 5 minutes), the supernatant is discarded, and Tris-ammonium chloride buffer (pH 7.65) For 1-2 minutes to remove red blood cells, washed three times with MEM, and used for cell fusion.
- the 8-azaguanine-resistant mouse myeloma cell line P3-U1 was cultured in a normal medium to secure 2 ⁇ 10 7 or more cells at the time of cell fusion and used as a parent strain for cell fusion.
- Rat splenocytes obtained in (1) and myeloma cells obtained in (2) were mixed at a ratio of 10: 1, centrifuged (1200 rpm, 5 minutes), and the supernatant was removed. discarded, precipitated with stirring at 37 ° C for the cells, 10 per two rat splenocytes 0.. 2 to 1.
- OML of fusion medium (2g of PEG-1000, 2 mL of MEM, dimethyl sulfoxide 0. 7 mL was added, and 1 to 2 mL of MEM was added several times every 1 to 2 minutes, and then MEM was further added so that the total volume became 50 mL. After centrifugation (900 rpm, 5 minutes), the supernatant was discarded, the cells were loosened gently, and suspended in 100 mL of HAT medium.
- the methylated BSA-hIGF- ⁇ prepared in Reference Example 1 (1) and methylated BSA-BSA as a negative control were used.
- the above antigen was dispensed at a concentration of lOg / mL in 50 L / well into a 96-well ELISA plate (manufactured by Greiner) at a concentration of hlGF-1 or BSA, and allowed to stand at 4 ° C for adsorption. After washing with PBS, PBS containing 1% BSA (hereinafter referred to as BSA-PBS) was added at 100 iL / well, and reacted at room temperature for 1 hour to block the remaining active groups.
- BSA-PBS PBS containing 1% BSA
- Tween-PBS PBS containing 0.05% Tween 20
- a 4000-fold diluted peroxidase-labeled heron anti-rat Ig antibody manufactured by DAK0 was used as a secondary antibody. And reacted at room temperature for 1 hour.
- FIG. 3 shows the results of the binding ELISA shown in Reference Example 1 (4), which showed that antibody KM1468 and a commercially available anti-hlGF-1 antibody sml.2 (Upstate
- hlGF-1 manufactured by Pepro Tech EC
- hIGF-II manufactured by Pepro Tech EC
- human insulin manufactured by Wako Pure Chemical Industries
- mIGF- The inhibitory activity by I was examined by the following competitive ELISA. Prepare a plate on which the antigen is immobilized as shown in Reference Example 1 (4), dispense various antibodies diluted to 4.0 zg / mL at 50 L / well, and serially dilute 3 times from 20 zg / niL.
- the reaction was performed for 1 hour.
- the plate was washed with Tween-PBS, and in the case of KM1468, a 4000-fold diluted peroxidase-labeled heron anti-rat Ig antibody (manufactured by DAK0), and in the case of sml.
- Ig antibody manufactured by DAK0
- the plate is washed with Tween-PBS and the ABTS substrate solution [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) ammonium] 0.55 is added to 1 L of 0.1 M citrate buffer.
- Concentration 50 is about 0.3 xg / mL (approximately 39 nM)
- IC 5 by hIGF- II indicated a value substantially equal to that of about 0.4 g / mL (approximately 58 nM).
- no inhibition was observed with human insulin and mlGF-1. From the above results, it was clarified that antibody 1468 reacts specifically with both hIGF-1 and hIGF-II with similar strength. The binding of commercially available anti-IGF-1 antibody sml.2 to hIGF-1 was strongly inhibited by MGF-I (FIG.
- hIGF_II the inhibitory activity by hIGF_II (FIG. 4B) was weak. While IC 5 by IilGF- 1 of sml.2 () was about 1 ⁇ 2 ng / mL (approximately 156nM), hIGF- II Nyoru 1 5. Was> 10 ⁇ / ⁇ (> 1.45 M). On the other hand, no inhibition was observed with human insulin and ml GF-I.
- the effect of the purified antibody KM1468 on hIGF-dependent cell proliferation was examined.
- the antibody used was KM1468, a commercially available anti-hIGF-I antibody sml.2 (Upstate biotechnology 3 ⁇ 4 And S1F2 (Upstate Biotechnology), which is a commercially available anti-hlGF-II antibody.
- Human breast cancer cell line MCF7 (ATCC HTB-22), human colon cancer cell line HT-29 (ATCC HTB-38) or human osteosarcoma cell line MG-63 (ATCC CRL-1427) in TF / BSA medium (D-MEM / F-12 (Gibco BRL) supplemented with 10 g / mL human transferrin (Gibco BRL) and 200 ⁇ g / mL BSA] to a concentration of 0.5 to 1 ⁇ 10 5 cells / mL.
- TF / BSA medium D-MEM / F-12 (Gibco BRL) supplemented with 10 g / mL human transferrin (Gibco BRL) and 200 ⁇ g / mL BSA] to a concentration of 0.5 to 1 ⁇ 10 5 cells / mL.
- each factor of MGF-I, hIGF-II or human insulin diluted to various concentrations in TF / BSA medium was diluted at 50 / z L / well, and each antibody diluted to various concentrations in TF / BSA medium was isolated. It was added at 50 / iL / Ueru, 37 ° C, and cultured for 5 days at 53 ⁇ 4 C0 2 incubator within one. After culture, cell proliferation reagent WST-1
- FIG. 5A shows a growth curve of each factor of the human breast cancer cell line MCF7.
- Figure 5B shows the results in the presence of 40 ng / mL hlGF-1
- Figure 5C shows the results in the presence of 100 ng / mL MGF-II
- Figure 5D shows the results in the presence of 100 ng / mL human insulin.
- proliferation was observed when each antibody was added.
- KM1468 strongly inhibited cell proliferation by WGF-I and hIGF-II, and its activity was sml.2, a commercially available anti-hIGF_I antibody, and commercially available anti-! It was higher than the IIGF-II antibody S1F2.
- FIG. 6A shows a growth curve of each factor of the human colon cancer cell line HT-29.
- Figure 6B shows the presence of 10 ng / mL hIGF-II
- Figure 6C shows the presence of 10 ng / mL hlGF-II
- Figure 6D shows the presence of 20 ng / mL human insulin. However, the growth was observed when each antibody was added.
- KM1468 inhibited cell proliferation by MGF-I and hIGF-II equally strongly, and its activity was determined by the commercial anti-WGF-I antibody sml.2 and commercial Higher than that of S1F2, which is an anti-hIGF-II antibody. On the other hand, none of the antibodies had any effect on the proliferation by human insulin. The above results are shown in Reference Example 2.
- FIG. 7A shows a growth curve of each factor of the human osteosarcoma cell line MG-63.
- Figure 7B shows the presence of 20 ng / mL hlGF-1
- Figure 7C shows the presence of 20 ng / mL WGF-II
- Figure 7D shows the presence of 20 ng / mL human insulin.
- the growth was shown when each antibody was added.
- thigh 1468 inhibited cell proliferation by hIGF-I and hlGF-II equally strongly, and its activity was similar to that of commercial anti-WGF-1 antibody sml. It was higher than S1F2, which is an anti-WGF-II antibody.
- none of the antibodies had any effect on proliferation by human insulin.
- the above results correlated well with the binding specificity observed in the competitive ELISA of Reference Example 2 (2), and clearly showed that the binding of each antibody inhibited the function of each factor. Things.
- the synthesized peptides include GF-I at positions 1-18 (SEQ ID NO: 1; hereinafter, referred to as pi-18), 14-30 (SEQ ID NO: 2, hereinafter referred to as P14-30), 24- 35th (SEQ ID NO: 3; hereinafter referred to as p24-35), 29-41 (SEQ ID NO: 4; hereinafter referred to as p29-41), 36-47 (SEQ ID NO: 5; hereinafter, p36-47) ), 41-56 (sequence number 6; hereinafter, referred to as p4 56), 52-70 (sequence number 7; hereinafter, referred to as p52_70), 53-61 (sequence number 8) ; Hereinafter referred to as P53-61) and peptides corresponding to the 61st to 70th positions (SEQ ID NO: 9;
- Cys a sequence substituted with Ser or Ala was synthesized.
- p4-56C a sequence having an internal Cys
- ABTS substrate solution [2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) 0.55 g of ammonium is added to 1 L of 0.1 M citrate buffer
- the pharmaceutical composition for treating cancer of the present invention comprises insulin-like growth factor-1 (IGF-I) and insulin-like growth factor-1.
- IGF-I insulin-like growth factor-1
- Combining a substance that inhibits the activity of IGF-II with a substance that has radiation or anti-tumor activity can enhance the therapeutic effect on cancer compared to when each is administered alone. it can.
- the dose of the drug can be reduced as compared with the case of administering alone, and the combination substance can be selected according to the patient's symptoms (type of cancer, severity of cancer).
- Advantageous effects can be obtained, such as being able to do so and maintaining the treatment period by selecting concomitant substances with different mechanisms of action.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002540133A CA2540133A1 (en) | 2003-09-24 | 2004-09-24 | Drugs for treating cancer |
JP2005514151A JPWO2005027970A1 (ja) | 2003-09-24 | 2004-09-24 | 癌治療用医薬 |
US10/573,528 US20060193772A1 (en) | 2003-09-24 | 2004-09-24 | Drugs for treating cancer |
EP04773540A EP1671647A1 (en) | 2003-09-24 | 2004-09-24 | Medicament for treating cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003332346 | 2003-09-24 | ||
JP2003-332346 | 2003-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005027970A1 true WO2005027970A1 (ja) | 2005-03-31 |
Family
ID=34373070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/014452 WO2005027970A1 (ja) | 2003-09-24 | 2004-09-24 | 癌治療用医薬 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060193772A1 (ja) |
EP (1) | EP1671647A1 (ja) |
JP (1) | JPWO2005027970A1 (ja) |
CA (1) | CA2540133A1 (ja) |
WO (1) | WO2005027970A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010045315A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
US8318159B2 (en) | 2008-12-12 | 2012-11-27 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
US8410058B2 (en) | 2005-12-13 | 2013-04-02 | Medimmune Limited | Methods of using insulin-like growth factor antibodies to treat tumors |
US8580254B2 (en) | 2007-06-19 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
US10377828B2 (en) | 2013-03-07 | 2019-08-13 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
CN101613409B (zh) * | 2005-06-17 | 2014-06-04 | 英克隆有限责任公司 | 抗-PDGFRα抗体 |
CA2625773C (en) * | 2005-10-14 | 2015-05-12 | Fukuoka University | Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation |
BRPI0617664B8 (pt) * | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
EP1990060B1 (en) * | 2006-01-27 | 2016-09-28 | Keio University | Therapeutic agents for diseases associated involving choroidal neovascularization |
CA2641310C (en) * | 2006-02-03 | 2013-08-20 | Imclone Systems Incorporated | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
WO2007116962A1 (ja) * | 2006-04-07 | 2007-10-18 | Osaka University | 筋再生促進剤 |
CA2661024A1 (en) * | 2006-08-28 | 2008-03-06 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
TWI438208B (zh) * | 2007-01-23 | 2014-05-21 | Chugai Pharmaceutical Co Ltd | 抑制慢性排斥反應之藥劑 |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US20110165145A1 (en) * | 2008-05-09 | 2011-07-07 | Dransfield Daniel T | Igf-ii/igf-iie binding proteins |
CA2728243C (en) * | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
US20100316639A1 (en) | 2009-06-16 | 2010-12-16 | Genentech, Inc. | Biomarkers for igf-1r inhibitor therapy |
EP4115906A1 (en) | 2010-05-28 | 2023-01-11 | Chugai Seiyaku Kabushiki Kaisha | Antitumor t cell response enhancer |
JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501411A (ja) * | 1993-06-11 | 1997-02-10 | アイ ビチャー,ハイム | 抗−新生物組成物及びその使用方法 |
JP2002512792A (ja) * | 1998-04-23 | 2002-05-08 | ジェネセンス テクノロジーズ インコーポレイテッド | インスリン様増殖因子iiアンチセンスオリゴヌクレオチド配列および細胞増殖を調節するためのその使用方法 |
JP2003520195A (ja) * | 1999-05-14 | 2003-07-02 | イムクローン システムズ インコーポレイティド | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5476779A (en) * | 1992-09-30 | 1995-12-19 | University Of Maryland At College Park | DNA encoding insulin-like growth factor II isolated from rainbow trout |
US6048534A (en) * | 1993-07-15 | 2000-04-11 | Board Of Regents The University Of Texas System | Methods and compositions for the selective regulation of chorionic prostanoids |
-
2004
- 2004-09-24 JP JP2005514151A patent/JPWO2005027970A1/ja active Pending
- 2004-09-24 CA CA002540133A patent/CA2540133A1/en not_active Abandoned
- 2004-09-24 WO PCT/JP2004/014452 patent/WO2005027970A1/ja not_active Application Discontinuation
- 2004-09-24 US US10/573,528 patent/US20060193772A1/en not_active Abandoned
- 2004-09-24 EP EP04773540A patent/EP1671647A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09501411A (ja) * | 1993-06-11 | 1997-02-10 | アイ ビチャー,ハイム | 抗−新生物組成物及びその使用方法 |
JP2002512792A (ja) * | 1998-04-23 | 2002-05-08 | ジェネセンス テクノロジーズ インコーポレイテッド | インスリン様増殖因子iiアンチセンスオリゴヌクレオチド配列および細胞増殖を調節するためのその使用方法 |
JP2003520195A (ja) * | 1999-05-14 | 2003-07-02 | イムクローン システムズ インコーポレイティド | 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理 |
Non-Patent Citations (3)
Title |
---|
DUNN S. E. ET AL.: "A Dominant Negative Mutant of the Insulin-like Growth Factor-I Receptor Inhibits the Adhesion, Invasion, and Metastasis of Breast Cancer", CANCER RESEARCH, vol. 58, no. 15, 1998, pages 3353 - 3361, XP002982677 * |
GOYA M. ET AL.: "Growth Inhibition of Human Prostate Cancer Cells in Human Adult Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors", CANCER RESEARCH, vol. 64, no. 17, 2004, pages 6252 - 6258, XP002982679 * |
WANG Y. ET AL.: "Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis", CURRENT CANCER DRUG TARGETS, vol. 2, no. 3, 2002, pages 191 - 207, XP002982678 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8410058B2 (en) | 2005-12-13 | 2013-04-02 | Medimmune Limited | Methods of using insulin-like growth factor antibodies to treat tumors |
US9181336B2 (en) | 2005-12-13 | 2015-11-10 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
US9796779B2 (en) | 2005-12-13 | 2017-10-24 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
US8580254B2 (en) | 2007-06-19 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
WO2010045315A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
US8318159B2 (en) | 2008-12-12 | 2012-11-27 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
EP3064219A2 (en) | 2008-12-12 | 2016-09-07 | Boehringer Ingelheim International GmbH | Anti-igf antibodies |
US10179810B2 (en) | 2008-12-12 | 2019-01-15 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
US11299538B2 (en) | 2008-12-12 | 2022-04-12 | Boehringer Ingelheim International Gmbh | Anti-IGF antibodies |
US10377828B2 (en) | 2013-03-07 | 2019-08-13 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
US9498540B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Cell proliferation inhibitors and conjugates thereof |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005027970A1 (ja) | 2007-11-15 |
CA2540133A1 (en) | 2005-03-31 |
EP1671647A1 (en) | 2006-06-21 |
US20060193772A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005027970A1 (ja) | 癌治療用医薬 | |
EP1505075B1 (en) | Antibody to human insulin-like growth factor | |
US7498415B2 (en) | Recombinant antibody against human insulin-like growth factor | |
EP4186926A1 (en) | Ccr8 antibody and application thereof | |
RU2506276C2 (ru) | Axl-антитела | |
JP5631733B2 (ja) | 抗EpCAM抗体およびその使用 | |
EP2168599B1 (en) | Cancer remedy containing antibody against peptide encoded by exon-17 of periostin | |
US20060263362A1 (en) | Cancer metastasis inhibitor | |
KR20230132544A (ko) | 신규한 항-그렘린1 항체 | |
JP4152315B2 (ja) | 線維芽細胞増殖因子−8に対するヒト化抗体および該抗体断片 | |
US11485779B2 (en) | Anti-BMP10 monoclonal antibody or fragment thereof | |
JP2003310275A (ja) | ヒトインスリン様成長因子に対する遺伝子組換え抗体 | |
KR101206318B1 (ko) | 자궁 내막증 치료제 | |
US11970531B2 (en) | Methods for treating hypertension using an anti-BMP10 monoclonal antibody or fragment thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2540133 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006193772 Country of ref document: US Ref document number: 10573528 Country of ref document: US Ref document number: 2005514151 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004773540 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004773540 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10573528 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004773540 Country of ref document: EP |